MCID: WLD002
MIFTS: 63

Waldenstrom Macroglobulinemia

Categories: Rare diseases, Neuronal diseases, Blood diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Waldenstrom Macroglobulinemia

MalaCards integrated aliases for Waldenstrom Macroglobulinemia:

Name: Waldenstrom Macroglobulinemia 38 50 25 29 52 69 25 56
Macroglobulinemia of Waldenstrom 50 25
Malignant Lymphoma - Lymphoplasmacytic 69
Waldenstrom's Macroglobulinaemia 50
Waldenstrom's Macroglobulinemia 25
Lymphoplasmacytic Lymphoma 50
Waldenstrom's Syndrome 50
Wm 25

Characteristics:

Orphanet epidemiological data:

56
waldenström macroglobulinemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:



Summaries for Waldenstrom Macroglobulinemia

NIH Rare Diseases : 50 waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. it usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. affected individuals have a high level of an antibody called immunoglobulin m (igm) in their blood, which can cause thickening of the blood (hyperviscosity). although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. other symptoms may include peripheral neuropathy, fever, raynaud's phenomenon, and mental status changes. hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. the cause of the condition is not known but environmental, genetic, and viral factors have been suggested. there have been some reports of familial cases suggesting a genetic predisposition. treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues. last updated: 10/1/2013

MalaCards based summary : Waldenstrom Macroglobulinemia, also known as macroglobulinemia of waldenstrom, is related to lymphoplasmacytic lymphoma and macroglobulinemia, waldenstrom 1, and has symptoms including ataxia, recurrent infections and diarrhea. An important gene associated with Waldenstrom Macroglobulinemia is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are Akt Signaling and NF-KappaB Family Pathway. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are shRNA abundance <= 50% and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Waldenstrom Macroglobulinemia

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 2 Macroglobulinemia, Waldenstrom 1

Diseases related to Waldenstrom Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Related Disease Score Top Affiliating Genes
1 lymphoplasmacytic lymphoma 11.4
2 macroglobulinemia, waldenstrom 1 11.1
3 macroglobulinemia 10.9
4 gamma heavy chain disease 10.6 CD40LG MYD88
5 colonic benign neoplasm 10.5 CD40LG MYD88
6 delta chain disease 10.5 CD40LG MYD88
7 mixed malaria 10.4 CD40LG MYD88
8 moved to 614436 10.4 CD40 CD40LG
9 blood group incompatibility 10.3 BCL2 CD40LG
10 periarthritis 10.3 CD40 CD40LG
11 epileptic encephalopathy, early infantile, 33 10.3 CD40 CD40LG
12 nasopharyngitis 10.3 CD40LG MYD88
13 immunoglobulin alpha deficiency 10.3 CD40 CD40LG
14 hypoparathyroidism, x-linked 10.3 CD40 CD40LG
15 ischemic optic neuropathy 10.3 CXCR4 PAX5
16 caplan's syndrome 10.3 CD40LG HAS1
17 spinal polio 10.2 CD40 CD40LG
18 nuchal bleb, familial 10.2 CD40LG IGHM
19 arteriosclerosis 10.2 CD40LG CXCR4 MYD88
20 villoglandular endometrial endometrioid adenocarcinoma 10.2 CD40LG PAX5
21 lymphoma 10.2
22 melanoma metastasis 10.2 BCL2 CD40LG MYD88
23 ehlers-danlos syndrome, periodontal type, 1 10.1 CD40 CD40LG
24 multiple myeloma 10.1
25 hypervitaminosis d 10.1 CD40 CD40LG MYD88
26 uterine corpus epithelioid leiomyosarcoma 10.0 CD40 CD40LG CXCR4
27 drug-induced hepatitis 10.0 BCL2 MYD88 PAX5
28 malignant melanocytic peripheral nerve sheath tumor of mediastinum 10.0 CD40 CD40LG
29 agammaglobulinemia, microcephaly, and severe dermatitis 10.0 CD40LG ZAP70
30 lymphoma, malt, somatic 10.0 BCL2 CD40 CD40LG
31 megakaryocytic leukemia 9.9 BCL2 CD40 CD40LG
32 retinitis 9.9
33 leukemia 9.9
34 brain germinoma 9.9 CD40 CD40LG
35 trachoma 9.9 CD40LG IGHM
36 seckel syndrome 10 9.8 CD40 CD40LG PAX5
37 heart sarcoma 9.8 CD40LG CXCR4
38 hepatic osteogenic sarcoma 9.8 PAX5 ZAP70
39 chronic lymphocytic leukemia 9.8
40 diffuse large b-cell lymphoma 9.8
41 pancreatitis 9.8
42 hematologic cancer 9.8
43 retinal detachment 9.8
44 hepatitis 9.8
45 polycythemia 9.8
46 neuropathy 9.8
47 mantle cell lymphoma 9.8
48 retinal vein occlusion 9.8
49 amyloidosis 9.8
50 sinusitis 9.8

Comorbidity relations with Waldenstrom Macroglobulinemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Neutropenia

Graphical network of the top 20 diseases related to Waldenstrom Macroglobulinemia:



Diseases related to Waldenstrom Macroglobulinemia

Symptoms & Phenotypes for Waldenstrom Macroglobulinemia

Human phenotypes related to Waldenstrom Macroglobulinemia:

56 32 (show all 46)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 56 32 occasional (7.5%) Occasional (29-5%) HP:0001251
2 recurrent infections 56 32 occasional (7.5%) Occasional (29-5%) HP:0002719
3 diarrhea 56 32 occasional (7.5%) Occasional (29-5%) HP:0002014
4 migraine 56 32 occasional (7.5%) Occasional (29-5%) HP:0002076
5 hepatomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0002240
6 splenomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0001744
7 peripheral neuropathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0009830
8 proptosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000520
9 fatigue 56 32 occasional (7.5%) Occasional (29-5%) HP:0012378
10 renal insufficiency 56 32 occasional (7.5%) Occasional (29-5%) HP:0000083
11 cutis marmorata 56 32 occasional (7.5%) Occasional (29-5%) HP:0000965
12 memory impairment 56 32 occasional (7.5%) Occasional (29-5%) HP:0002354
13 epistaxis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000421
14 purpura 56 32 occasional (7.5%) Occasional (29-5%) HP:0000979
15 fever 56 32 occasional (7.5%) Occasional (29-5%) HP:0001945
16 malabsorption 56 32 occasional (7.5%) Occasional (29-5%) HP:0002024
17 congestive heart failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0001635
18 respiratory insufficiency 56 32 frequent (33%) Frequent (79-30%) HP:0002093
19 stroke 56 32 occasional (7.5%) Occasional (29-5%) HP:0001297
20 lymphadenopathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0002716
21 vertigo 56 32 frequent (33%) Frequent (79-30%) HP:0002321
22 leukemia 56 32 hallmark (90%) Very frequent (99-80%) HP:0001909
23 lymphoma 56 32 hallmark (90%) Very frequent (99-80%) HP:0002665
24 vasculitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0002633
25 periorbital edema 56 32 occasional (7.5%) Occasional (29-5%) HP:0100539
26 retinal hemorrhage 56 32 occasional (7.5%) Occasional (29-5%) HP:0000573
27 multifocal epileptiform discharges 56 32 occasional (7.5%) Occasional (29-5%) HP:0010841
28 pleural effusion 56 32 occasional (7.5%) Occasional (29-5%) HP:0002202
29 pulmonary infiltrates 56 32 occasional (7.5%) Occasional (29-5%) HP:0002113
30 pallor 56 32 frequent (33%) Frequent (79-30%) HP:0000980
31 hearing impairment 56 32 occasional (7.5%) Occasional (29-5%) HP:0000365
32 gingival bleeding 56 32 frequent (33%) Frequent (79-30%) HP:0000225
33 urticaria 56 32 occasional (7.5%) Occasional (29-5%) HP:0001025
34 anorexia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002039
35 normocytic anemia 56 32 frequent (33%) Frequent (79-30%) HP:0001897
36 cranial nerve paralysis 56 32 occasional (7.5%) Occasional (29-5%) HP:0006824
37 gastrointestinal hemorrhage 56 32 occasional (7.5%) Occasional (29-5%) HP:0002239
38 elevated erythrocyte sedimentation rate 56 32 occasional (7.5%) Occasional (29-5%) HP:0003565
39 edema of the lower limbs 56 32 occasional (7.5%) Occasional (29-5%) HP:0010741
40 cryoglobulinemia 56 32 occasional (7.5%) Occasional (29-5%) HP:0100778
41 reduced consciousness/confusion 56 32 occasional (7.5%) Occasional (29-5%) HP:0004372
42 hypercoagulability 56 32 frequent (33%) Frequent (79-30%) HP:0100724
43 abnormality of the retinal vasculature 56 32 occasional (7.5%) Occasional (29-5%) HP:0008046
44 abnormality of neutrophils 56 32 frequent (33%) Frequent (79-30%) HP:0001874
45 waldenstrom macroglobulinemia 56 Very frequent (99-80%)
46 monoclonal immunoglobulin m proteinemia 32 hallmark (90%) HP:0005508

GenomeRNAi Phenotypes related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.5 BCL2 CD40 CXCR4 HAS1 MYD88 PAX5
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CXCR4 MYD88 BCL2 CD40LG
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 MYD88 BCL2 CD40 CD40LG CXCR4

MGI Mouse Phenotypes related to Waldenstrom Macroglobulinemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 BCL2 CD40 CD40LG CXCR4 MYD88 ZAP70
2 hematopoietic system MP:0005397 9.8 BCL2 CD40 CD40LG CXCR4 MYD88 PAX5
3 immune system MP:0005387 9.7 ZAP70 BCL2 CD40 CD40LG CXCR4 MYD88
4 renal/urinary system MP:0005367 9.35 BCL2 CD40 CD40LG CXCR4 MYD88
5 skeleton MP:0005390 9.1 CD40 CD40LG CXCR4 MYD88 PAX5 ZAP70

Drugs & Therapeutics for Waldenstrom Macroglobulinemia

Drugs for Waldenstrom Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 375)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
3 Thiotepa Approved Phase 4,Phase 2,Phase 3 52-24-4 5453
4
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
7
Cytarabine Approved, Investigational Phase 4,Phase 1,Phase 2 147-94-4 6253
8
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
9
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-24-8 5755
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
24 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
32
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2
35 Angiogenesis Modulating Agents Phase 4,Phase 1,Phase 2
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Antibodies Phase 4,Phase 2,Phase 1,Early Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
41 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
43 Immunoglobulins Phase 4,Phase 2,Phase 1,Early Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
45 Protective Agents Phase 4,Phase 2,Phase 1
46 Vitamin B Complex Phase 4,Phase 2,Phase 1,Early Phase 1
47 Methylprednisolone acetate Phase 4,Phase 2,Phase 1
48 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 1
49 Neuroprotective Agents Phase 4,Phase 2,Phase 1
50 Prednisolone acetate Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 458)

id Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
12 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
13 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
14 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
15 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
18 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
19 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
20 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
21 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
22 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
23 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
24 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
25 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
28 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
29 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
30 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
31 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
32 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Active, not recruiting NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
33 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Active, not recruiting NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
37 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
38 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
39 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
40 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia Unknown status NCT00003512 Phase 2 antineoplaston A10;antineoplaston AS2-1
41 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
42 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
43 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2 lenalidomide;carmustine;etoposide;cytarabine;melphalan
44 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
45 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
46 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
47 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
48 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
49 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
50 Sildenafil Citrate in Waldenstrom's Macroglobulinemia Completed NCT00165295 Phase 2 Sildenafil citrate (Viagra)

Search NIH Clinical Center for Waldenstrom Macroglobulinemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Waldenstrom Macroglobulinemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Waldenstrom Macroglobulinemia:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Waldenstrom Macroglobulinemia:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Waldenstrom Macroglobulinemia

Genetic tests related to Waldenstrom Macroglobulinemia:

id Genetic test Affiliating Genes
1 Waldenstrom Macroglobulinemia 29

Anatomical Context for Waldenstrom Macroglobulinemia

MalaCards organs/tissues related to Waldenstrom Macroglobulinemia:

39
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Liver, Kidney

Publications for Waldenstrom Macroglobulinemia

Articles related to Waldenstrom Macroglobulinemia:

(show top 50) (show all 136)
id Title Authors Year
1
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. ( 28583038 )
2018
2
Dexamethasone, rituximab and cyclophosphamide for relapsedA and/or refractory and treatment-naA^ve patients with Waldenstrom macroglobulinemia. ( 28786474 )
2017
3
A Case of Waldenstrom Macroglobulinemia with Temporary Appearance of 7S IgM Half Molecule. ( 28627827 )
2017
4
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. ( 28548645 )
2017
5
Significances of MYD88(L265P) and CXCR4(WHIM) Mutations in Waldenstrom Macroglobulinemia. ( 28877839 )
2017
6
Waldenstrom macroglobulinemia presenting as a bilateral subdural chronic hematoma. ( 28262409 )
2017
7
UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. ( 28106626 )
2017
8
EDTA-induced pseudothrombocytosis and citrate-induced platelet agglutination in a patient with Waldenstrom macroglobulinemia. ( 28781833 )
2017
9
A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission. ( 28883220 )
2017
10
Waldenstrom macroglobulinemia: prognosis and management. ( 26849012 )
2016
11
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. ( 27696269 )
2016
12
A 44-Year-Old Man with Waldenstrom Macroglobulinemia and Bilateral Maxillary Sinusitis. ( 27840358 )
2016
13
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. ( 27813535 )
2016
14
Novel therapeutic targets in Waldenstrom macroglobulinemia. ( 27825468 )
2016
15
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. ( 27268124 )
2016
16
Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. ( 26942591 )
2016
17
Learning from Waldenstrom Macroglobulinemia. ( 27825458 )
2016
18
Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. ( 27722129 )
2016
19
Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). ( 27836860 )
2016
20
Waldenstrom macroglobulinemia: prognosis and management. ( 25815903 )
2015
21
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia. ( 25703132 )
2015
22
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. ( 26139427 )
2015
23
Waldenstrom Macroglobulinemia Mimicking Temporal Arteritis. ( 25996301 )
2015
24
Characteristic OCT Pattern in Waldenstrom Macroglobulinemia. ( 25871872 )
2015
25
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. ( 24622324 )
2014
26
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. ( 24553177 )
2014
27
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. ( 24716234 )
2014
28
Waldenstrom macroglobulinemia: genetics dictates clinical course. ( 24786453 )
2014
29
Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line. ( 24189269 )
2014
30
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. ( 25060991 )
2014
31
Detection of erythrocytes in patients with Waldenstrom macroglobulinemia using atomic force microscopy. ( 24675428 )
2014
32
Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature. ( 23306344 )
2013
33
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia. ( 23355206 )
2013
34
MYD88 L265P mutation in Waldenstrom macroglobulinemia. ( 23532735 )
2013
35
A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. ( 23773449 )
2013
36
A new era for Waldenstrom macroglobulinemia: MYD88 L265P. ( 23723443 )
2013
37
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. ( 23861223 )
2013
38
Choice of therapy for patients with Waldenstrom macroglobulinemia. ( 23233705 )
2013
39
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). ( 24004667 )
2013
40
Waldenstrom macroglobulinemia presenting as isolated persistent epistaxis: a very rare presentation. ( 24427564 )
2013
41
Are you sure this is Waldenstrom macroglobulinemia? ( 23233639 )
2012
42
Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. ( 22139816 )
2012
43
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. ( 22879385 )
2012
44
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. ( 23048077 )
2012
45
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. ( 21732338 )
2012
46
Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. ( 22404949 )
2012
47
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. ( 22976953 )
2012
48
Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data. ( 22100692 )
2012
49
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. ( 22099500 )
2012
50
Waldenstrom macroglobulinemia with a durable clinical response to epoetin beta. ( 22260157 )
2012

Variations for Waldenstrom Macroglobulinemia

Expression for Waldenstrom Macroglobulinemia

Search GEO for disease gene expression data for Waldenstrom Macroglobulinemia.

Pathways for Waldenstrom Macroglobulinemia

Pathways related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 BCL2 CD40 CD40LG CXCR4 MYD88 ZAP70
2
Show member pathways
12.43 CD40 CD40LG MYD88 ZAP70
3
Show member pathways
12.36 BCL2 CD40 CD40LG MYD88
4
Show member pathways
12.35 CD40 CD40LG IGHM ZAP70
5
Show member pathways
12.12 CD40 CD40LG ZAP70
6 12.05 CD40LG CXCR4 MYD88 PAX5 ZAP70
7 11.97 BCL2 CD40LG CXCR4
8
Show member pathways
11.94 BCL2 CD40 CD40LG MYD88
9
Show member pathways
11.5 BCL2 CD40 CD40LG
10 11.45 CD40 CD40LG PAX5
11 11.35 CD40 CD40LG
12 11.27 CD40 CD40LG MYD88
13 11.1 CD40 CD40LG
14 11.07 CD40 CD40LG ZAP70
15 11.02 CD40 CD40LG
16 11 BCL2 CD40 CD40LG MYD88 ZAP70
17 10.98 CD40 CD40LG CXCR4 PAX5
18 10.95 CD40 CD40LG ZAP70

GO Terms for Waldenstrom Macroglobulinemia

Cellular components related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.13 CD40 CD40LG IGHM
2 cell surface GO:0009986 8.92 CD40 CD40LG CXCR4 IGHM

Biological processes related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.63 CD40 MYD88 ZAP70
2 immune system process GO:0002376 9.54 CD40 MYD88 ZAP70
3 humoral immune response GO:0006959 9.51 BCL2 PAX5
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.5 CD40 CD40LG MYD88
5 positive regulation of B cell proliferation GO:0030890 9.49 BCL2 CD40
6 T cell differentiation GO:0030217 9.48 BCL2 ZAP70
7 inflammatory response GO:0006954 9.46 CD40 CD40LG CXCR4 MYD88
8 B cell activation GO:0042113 9.43 CD40 ZAP70
9 positive regulation of interleukin-12 production GO:0032735 9.4 CD40 CD40LG
10 positive regulation of endothelial cell apoptotic process GO:2000353 9.26 CD40 CD40LG
11 regulation of immunoglobulin secretion GO:0051023 8.96 CD40 CD40LG
12 B cell proliferation GO:0042100 8.8 BCL2 CD40 CD40LG

Molecular functions related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 8.8 BCL2 CD40 CXCR4

Sources for Waldenstrom Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....